Numerous studies support a role for Sox2 to keep stem cells and progenitor cells in an immature and proliferative state. Coexpression of Sox2 and GFAP has been found in regions of the adult brain where neural stem cells are present and in human glioma cells. In our study, we have investigated the roles of Sox2 and its counteracting partner Sox21 in human glioma cells. We show for the first time that Sox21 is expressed in both primary glioblastoma and in human glioma cell lines. We found that coexpression of Sox2, GFAP and Sox21 was mutually exclusive with expression of fibronectin. Our result suggests that glioma consists of at least two different cell populations: Sox2(+) /GFAP(+) /Sox21(+) /FN(-) and Sox2(-) /GFAP(-) /Sox21(-) /FN(+) . Reduction of Sox2 expression by using siRNA against Sox2 or by overexpressing Sox21 using a tetracycline-regulated expression system (Tet-on) caused decreased GFAP expression and a reduction in cell number due to induction of apoptosis. We suggest that Sox21 can negatively regulate Sox2 in glioma. Our findings imply that Sox2 and Sox21 may be interesting targets for the development of novel glioma therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ijc.25647 | DOI Listing |
Sci Rep
January 2025
Department of Biochemistry and Molecular Biology, Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Key Laboratory of Coal Environmental Pathogenicity and Prevention (Ministry of Education, China, Shanxi Medical University, No. 56, Xinjian South Road, Yingze District, Taiyuan City, 030000, Shanxi Province, China.
There are many similarities between early embryonic development and tumorigenesis. The occurrence of neural tube defects (NTDs) and glioblastoma (GBM) are both related to the abnormal development of neuroectodermal cells. To obtain genes related to both NTDs and GBM, as well as small molecule drugs with potential clinical application value.
View Article and Find Full Text PDFNat Commun
January 2025
Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Oncolytic viruses (OVs) emerge as a promising cancer immunotherapy. However, the temporal impact on tumor cells and the tumor microenvironment, and the nature of anti-tumor immunity post-therapy remain largely unclear. Here we report that CD4 T cells are required for durable tumor control in syngeneic murine models of glioblastoma multiforme after treatment with an oncolytic herpes simplex virus (oHSV) engineered to express IL-12.
View Article and Find Full Text PDFNo Shinkei Geka
January 2025
Division of Neurosurgery, Tohoku Medical and Pharmaceutical University.
This study reviews the diagnostic criteria and treatment strategies for spinal malignant gliomas, particularly glioblastoma with -wildtype and diffuse midline gliomas with H3-K27 alteration, according to the World Health Organization 2021 classification. Surgical resection remains challenging owing to the diffuse nature of these tumors. Even with the Stupp regimen(temozolomide and radiotherapy), the prognosis remains poor, with an average survival of 12 months.
View Article and Find Full Text PDFNo Shinkei Geka
January 2025
Department of Neurosurgery, Osaka Medical and Pharmaceutical University.
Surgery for spinal intramedullary tumors remains a major challenge for neurosurgeons. Successful surgery requires experience, skill, and intraoperative imaging support. Fluorescence imaging technology has become a valuable support in neurosurgical procedures of not only the brain but also the spinal cord.
View Article and Find Full Text PDFCurr Nutr Rep
January 2025
Department of Vascular Surgery, Mount Sinai Hospital, 1468 Madison Ave, New York, NY, 10029, USA.
PURPOSE OF REVIEW: A Ketogenic diet (KD; a diet comprised of 75% fat, 20% protein and 5% carbohydrates) has gained much popularity in recent years, especially regarding neurogliomas (or "gliomas"). This review critically assesses literature on the application of KD throughout the cancer continuum from a Medical Nutrition Therapy (MNT) perspective. RECENT FINDINGS: 2021 revised classification standards for Central Nervous System (CNS) tumors are available.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!